The Question

By carrying out this case study, we wanted
to know: Can technology driven patient
communities truly work towards driving
engagement and adherence?

The Challenge

A global pharmaceutical brand partnered with
RxPx to help solve the challenge of therapy
discontinuation. Clinical trials showed a 50%
discontinuation and poor adherence of this pharmaceutical brands therapy within the first 8 weeks.

This was attributed to several challenges: difficulty staying adherent to 2x daily oral oncolytic, older age of the patient population (average age range of 65-74), and side effects.

Click to read the full case study and find out about how 

RxPX powered this major global pharma brand to launch

an app-based patient community.
Read the Case Study

The Results

%

97% of patients remained
in app for at least 90
days, compared to
industry average of
31%**

%

70% of patients remained
in app for at least 1 year,
compared to industry
average of 18%**

%

52% of patients launch the
app 10 times or more in 30
days, compared to industry
average of 17%**